We live in a data-driven world where data has the potential to optimize business performance, transform operations, improve ROI, provide better insights and maximize human potential. Despite the immense traction, data has gained in recent times; there has always been a problem around analyzing unstructured data. Organizations are now looking for ways to analyze unstructured data to get the most value out of their information. Unstructured data has immense business value, but many companies have not yet managed to yield insights due to the challenges in discovering and analyzing unstructured data. Some of the challenges posed by unstructured data are continuous expansion, conventional systems, poor data quality, and irrelevant information. Globally, there are various companies specializing in providing solutions for unstructured data analysis, But Adlib stands out from the rest.
Adlib serves many large enterprise organizations in several major industries such as; Banking, Insurance, Pharmaceuticals & Life Sciences, Oil, Gas & Energy and Manufacturing helping to reimagine business by transforming their content into intelligent data. Some of these companies includes; Pfizer, AstraZeneca, British Petroleum, Nationwide, SwissRe, IAG, State Street, ABB, BMW, PwC. In addition to North America, the company is quite strong in the European Union and has clients in Australia and Asia. As it has grown geographically, the offerings have become quite diverse and certainly grown by many orders of magnitude in terms of workforce and revenues. That healthy trajectory continues today with Diversis Capital Partners adding significant investment to fuel even more growth.
Adding Modern Advancements to Leverage Clean Structured Data:
Adlib’s main motto is to create intelligent data to amplify human potential and maximize business performance. Its Content Intelligence Cloud and automation solutions make it easy to discover, standardize, classify, extract, and leverage clean structured data from complex unstructured documents. Across all functions, from Risk to Finance, to IT and Operations, the organization is ready to help enterprises unearth new market opportunities, reduce risk, simplify compliance, and enter a whole new level of performance. Marc Fuentes, SR. Director, Marketing and Sales Development, Adlib, asserts, “We help enterprise organizations leverage their content much better than they do today with our solutions. We help them transform unstructured content like documents and emails into structured formats acceptable for downstream systems that can interpret the data. We help our clients extract “stuck” data.” Up until now, organizations have just accepted that vast amounts of information are essentially lost. Using Adlib’s solutions, they’re able to reclaim that lost information leverage it and make data-driven decisions across their enterprise.
Business demands a complicated mixture of stable, proven technology and market-disrupting innovation. “Our 20 years of experience in mission-critical enterprise environments and a history of ongoing innovation and technology leadership give you both,” adds Marc.
A View on Pharmaceutical & Life Sciences Industry:
Adlib supports 90% of the Top Global Pharmaceutical / and Life Sciences with its Content Intelligence Cloud for Life Sciences taking unstructured content and leveraging them to derive a higher level of intelligence. That might be extracting data or sharing a document or contract in a way that one couldn’t be shared before. It might include making documents or contracts fully searchable through optical character recognition (OCR). It might also be classifying the document or contract based on type or other nomenclature or it might be producing perfectly rendered PDF submissions for FDA and or EMA to accelerate a life saving drug or device to market.
Adlib’s platform was designed to reverse this trend. Ultimately, it’s the ability to drive that information to downstream systems (regulatory information management, robotic process automation, contract lifecycle management, content management systems, data lakes, insight engines) that operate more effectively with more data that’s transformed to be intelligent.
In short, the platform is making unintelligent documents “intelligent” so they can help drive business process automation. “With 80% of data being unstructured by 2025, according to IDC, as quoted by Data Management Solutions Review, the challenge is on, but our Content Intelligence platform is the answer,” says Marc .
If one only thinks about pharmaceuticals and life sciences and only about the emails and documents created automatically and stored, all the data in those emails and documents are inaccessible and unusable. So, Content Intelligence is the opportunity to do something that couldn’t be done before, to bring that enormous volume of unstructured data, to bear productively on the enterprise. COVID 19 has shone a new light on that value in healthcare. The complexity of getting any data to be expressed consistently across different healthcare units has been shockingly inefficient.
Marc says, “If we are to tackle the disease on a global basis, data has to flow. Extrapolate that out into all businesses for purchase decisions and contracts and employment records and business records and all kinds of other data that are just stored in isolated records, just in case that single record has to be read one day. That seems almost crazy. Yet it’s routine. In aggregate, those records are chock full of data that can be leveraged to improve the business in obvious ways and new ways that haven’t even been conceived yet. The potential is really unlimited.” He further adds, “The risk side is often easier to sell because there’s an obvious and immediate value. Using our technologies, an organization’s full risk profile is revealed and then maintained. But after that, the technology starts to be appealing as a competitive tool for better understanding customers and making better business decisions. That’s one of the promises of big data. And unstructured data brought to life makes big data much bigger, thus not only fulfilling the promise but enlarging it.”
These days, every large enterprise has built an innovation team, usually with a C-level executive who focuses on innovation and data. They’ve all got data-transformation projects.
Using Advancement to Leading the Market:
Drug development has always been laborious and time-consuming. When a pharmaceutical or life sciences company initiates the development process of a new drug, extensive clinical trials are held before the compound is submitted to the FDA for approval. However, the pathway to drug approval generates a massive amount of information. The enormous quantity of unstructured data generated during the trials from email, MS office documents, and other unstructured content formats has to be appropriately sorted into a standardized format before submitting it to the FDA. This task can be quite complex in terms of formatting and creating high-quality, searchable hyperlinks with navigation-rich content that could go into regulatory submission ready-pdfs for FDA approval.
With its ability to simplify the most complicated datasets and extract valuable data from highly diverse and complex document formats, Adlib helps pharmaceutical and life sciences companies turn their unstructured data into a premium, searchable PDF output with all the necessary navigation elements in it. Adlib works with over 300 different file formats. Through its unique Content Intelligence Cloud platform, Adlib gathers unstructured data and brings actionable insights to unearth emergent market opportunities and business lifelines. It enables reviewers to efficiently quicken the review process and accelerate the time to approve life-saving drugs.
Leveraging cognitive technologies like AI and ML, the Adlib Content Intelligence Cloud platform executes humanlike operations such as automatically grouping and classifying similar content and applying a rich set of metadata tags for easier data search. By placing AI in the hands of everyday users, the company empowers even a non-data scientist to produce topflight data from documents with minimal effort than traditional methods.
Pacing to Add More Innovative Solutions in Future:
In due course of time, Adlib intends to further focus on its internal R&D data science team, which is developing advanced AI algorithms to teach computers to perform tasks more humanely. The company is also looking forward to building additional solution accelerators along with AI models and libraries. Meanwhile, Adlib is enabling pharmaceutical and life sciences companies to accelerate time to market and deal with the supply chain disruption unfolded by the on-going global health crisis. The company is planning to collate information flowing through the complex and dynamic supply chain, on the buy and supply side, and glean actionable insights.
The goal is to move beyond internal workflows and automation toward the edge where Adlib can help pharmaceuticals and life sciences reimagine business faster and use intelligent data to build, test, and deploy various business models required to achieve desired goals.
Renowned for its Services and Client-Centric Approach:
Building on a legacy spanning over 20 years in the pharmaceutical and life sciences industry, Adlib has always been able to meet its customer’s high demands, both in functionality and corporate security or auditability. The customer-centric approach of Adlib to execute data-driven strategies that thrive on automation streamlines various processes and workflows for numerous pharmaceuticals and life sciences organizations. Furthermore, Adlib’s professional services teams assist clients in installing, configuring, and deploying its solutions within their environment. In essence, it comes as no surprise that Adlib boast a prestigous portfolio of customers across the globe. Companies like Merck, Roche, J&J, and Pfizer, among others, utilize Adlib’s Technology to accelerate time to market.
Over the years, the company has been recognized as “Best Workplaces in Technology 2020,” and, for the third year in a row “Great Place To Work” award. In the insurance market, awarded InsurTech’s “Top 20 Solutions Providers 2020,” and in life sciences won “Most Promising Pharma & Life Sciences Tech Solution Providers 2020.” It’s also SOC 2 Type 1 Certified and HIPAA Certified.
